Investment giant advises 'conservative' allocation to digital assets for certain clients, signaling growing mainstream acceptance.
The pharmaceutical giant is now considered one of Morningstar's highest-conviction undervalued stocks, citing a robust pipeline and strategic acquisitions.
Institutional demand and economic uncertainty fuel the historic rally in the world's largest cryptocurrency, pushing the market into a bullish frenzy.
Pharmaceuticals, heavy trucks, and furniture targeted in a move that could spark fresh inflation fears and impact corporate profits.
The ongoing US government shutdown is delaying critical jobs and inflation reports, creating an information vacuum for investors and the Federal Reserve.
Shares fall despite strong Q3 sales, as expiring EV tax credits and valuation concerns spook investors.
The utility giant reaffirmed its adjusted EPS targets for 2025 and 2026, reinforcing a long-term earnings growth strategy of 7% to 9% through 2029.
A coalition of influential investors is urging shareholders to reject the CEO's new compensation package, citing major governance concerns.